Choreo LLC bought a new stake in shares of Fidelity National Financial, Inc. (NYSE:FNF - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 11,735 shares of the financial services provider's stock, valued at approximately $664,000.
A number of other institutional investors have also recently modified their holdings of the business. Charles Schwab Investment Management Inc. grew its position in shares of Fidelity National Financial by 3.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 8,025,159 shares of the financial services provider's stock valued at $498,041,000 after acquiring an additional 289,962 shares during the period. Geode Capital Management LLC lifted its stake in Fidelity National Financial by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 4,462,837 shares of the financial services provider's stock valued at $276,343,000 after buying an additional 69,643 shares in the last quarter. AustralianSuper Pty Ltd lifted its stake in Fidelity National Financial by 0.4% in the 3rd quarter. AustralianSuper Pty Ltd now owns 1,833,765 shares of the financial services provider's stock valued at $113,803,000 after buying an additional 6,976 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Fidelity National Financial by 3.9% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,530,424 shares of the financial services provider's stock valued at $94,978,000 after buying an additional 57,316 shares in the last quarter. Finally, FMR LLC lifted its stake in Fidelity National Financial by 11.4% in the 3rd quarter. FMR LLC now owns 872,017 shares of the financial services provider's stock valued at $54,117,000 after buying an additional 89,031 shares in the last quarter. 81.17% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of research analysts recently weighed in on FNF shares. Keefe, Bruyette & Woods decreased their price target on shares of Fidelity National Financial from $64.00 to $63.00 and set a "market perform" rating on the stock in a research note on Wednesday, January 8th. Deutsche Bank Aktiengesellschaft raised shares of Fidelity National Financial from a "hold" rating to a "buy" rating and raised their price target for the company from $76.00 to $77.00 in a research note on Friday, January 3rd. Finally, Truist Financial raised their price target on shares of Fidelity National Financial from $64.00 to $70.00 and gave the company a "buy" rating in a research note on Monday, November 11th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Fidelity National Financial has an average rating of "Moderate Buy" and an average target price of $66.40.
Get Our Latest Stock Report on Fidelity National Financial
Fidelity National Financial Price Performance
FNF traded up $0.21 during trading on Friday, reaching $57.91. The company's stock had a trading volume of 852,809 shares, compared to its average volume of 893,070. The company has a quick ratio of 0.24, a current ratio of 0.24 and a debt-to-equity ratio of 0.47. The firm has a fifty day simple moving average of $57.53 and a two-hundred day simple moving average of $58.86. Fidelity National Financial, Inc. has a 1 year low of $46.85 and a 1 year high of $64.83. The company has a market cap of $15.85 billion, a price-to-earnings ratio of 21.06 and a beta of 1.39.
Insiders Place Their Bets
In other news, Director Sandra Douglass Morgan sold 2,092 shares of Fidelity National Financial stock in a transaction that occurred on Tuesday, December 24th. The shares were sold at an average price of $56.33, for a total transaction of $117,842.36. Following the sale, the director now owns 32,386 shares of the company's stock, valued at approximately $1,824,303.38. The trade was a 6.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Halim Dhanidina sold 2,800 shares of Fidelity National Financial stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $54.85, for a total transaction of $153,580.00. Following the sale, the director now directly owns 16,716 shares in the company, valued at approximately $916,872.60. The trade was a 14.35 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.20% of the company's stock.
Fidelity National Financial Profile
(
Free Report)
Fidelity National Financial, Inc, together with its subsidiaries, provides various insurance products in the United States. The company operates through Title, F&G, and Corporate and Other segments. It offers title insurance, escrow, and other title related services, including trust activities, trustee sales guarantees, recordings and reconveyances, and home warranty products.
Read More

Before you consider Fidelity National Financial, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fidelity National Financial wasn't on the list.
While Fidelity National Financial currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.